Clinical Trials
4
Active:1
Completed:2
Trial Phases
2 Phases
Phase 1:2
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (50.0%)Phase 2
2 (50.0%)A Two-Part Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Repeat Doses of Inhaled ETD001 in People With Cystic Fibrosis
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2025-07-14
- Lead Sponsor
- Enterprise Therapeutics Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT06478706
- Locations
- 🇫🇷
Hospices Civils de Lyon, Lyon, France
🇫🇷CHU de Montpellier, Montpellier, France
🇫🇷Hôpital Cochin, Paris, France
A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD001 in Healthy Subjects
Phase 1
Completed
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: ETD001 multiple twice daily dosesDrug: ETD001 single doseDrug: Placebo single doseDrug: Placebo multiple twice daily dosesDrug: ETD001 multiple once daily dosesDrug: Placebo multiple once daily doses
- First Posted Date
- 2021-06-15
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- Enterprise Therapeutics Ltd
- Target Recruit Count
- 98
- Registration Number
- NCT04926701
- Locations
- 🇬🇧
Hammersmith Medicines Research, London, United Kingdom
A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD002 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: ETD002 - 14 day repeat doseDrug: ETD002 - single doseDrug: ETD002 - 7 day repeat doseDrug: Placebo - single doseDrug: Placebo - 14 day repeat doseDrug: Placebo - 7 day repeat dose
- First Posted Date
- 2020-07-28
- Last Posted Date
- 2021-05-21
- Lead Sponsor
- Enterprise Therapeutics Ltd
- Target Recruit Count
- 80
- Registration Number
- NCT04488705
- Locations
- 🇬🇧
Hammersmith Medicines Research, London, United Kingdom
News
No news found